NASDAQ:NURO NeuroMetrix (NURO) Stock Price, News & Analysis → Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad) Free NURO Stock Alerts $3.77 -0.06 (-1.57%) (As of 06/6/2024 ET) Add Compare Share Share Today's Range$3.73▼$3.8750-Day Range$3.51▼$4.7052-Week Range$2.70▼$9.20Volume2,885 shsAverage Volume35,131 shsMarket Capitalization$7.58 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get NeuroMetrix alerts: Email Address Ad Porter & CompanyThe only AI company to buyThe AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. About NeuroMetrix Stock (NASDAQ:NURO)NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.Read More NURO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NURO Stock News HeadlinesJune 5 at 1:26 AM | americanbankingnews.comNeuroMetrix (NASDAQ:NURO) Now Covered by Analysts at StockNews.comMay 29, 2024 | americanbankingnews.comNeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.comMay 28, 2024 | americanbankingnews.comNeuroMetrix (NASDAQ:NURO) Shares Pass Above 200-Day Moving Average of $3.71May 15, 2024 | globenewswire.comNeuroMetrix Reports Q1 2024 Business HighlightsApril 24, 2024 | finance.yahoo.comNeuroMetrix, Inc.'s (NASDAQ:NURO) CEO Might Not Expect Shareholders To Be So Generous This YearApril 20, 2024 | investing.comNeuroMetrix appoints new board director, ends ATM facilityApril 19, 2024 | markets.businessinsider.comNeuroMetrix Rises 18% After Announcement Of Shareholder Value Enhancement StepsApril 19, 2024 | finanznachrichten.deNeuroMetrix, Inc.: NeuroMetrix Announces Steps Taken to Enhance Shareholder ValueApril 19, 2024 | globenewswire.comNeuroMetrix Announces Steps Taken to Enhance Shareholder ValueMarch 14, 2024 | globenewswire.comNeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral NeuropathyMarch 13, 2024 | finanznachrichten.deNeuroMetrix, Inc.: NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell FibromyalgiaMarch 13, 2024 | globenewswire.comNeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® FibromyalgiaMarch 8, 2024 | finanznachrichten.deRS Fund Management LLC: RS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.March 8, 2024 | finance.yahoo.comRS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.February 25, 2024 | au.lifestyle.yahoo.comGoogle releases new open LLMs, Rivian lays off staff and Signal rolls out usernamesFebruary 24, 2024 | finance.yahoo.comNeuroMetrix Full Year 2023 Earnings: US$6.08 loss per share (vs US$4.96 loss in FY 2022)February 23, 2024 | finance.yahoo.comNeuroMetrix, Inc. (NASDAQ:NURO) Q4 2023 Earnings Call TranscriptFebruary 22, 2024 | finanznachrichten.deNeuroMetrix, Inc.: NeuroMetrix Reports Q4 and Full Year 2023 Business HighlightsFebruary 22, 2024 | finance.yahoo.comNeuroMetrix Reports Q4 and Full Year 2023 Business HighlightsFebruary 22, 2024 | globenewswire.comNeuroMetrix Reports Q4 and Full Year 2023 Business HighlightsFebruary 15, 2024 | finance.yahoo.comNeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference CallFebruary 15, 2024 | globenewswire.comNeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference CallFebruary 13, 2024 | finanznachrichten.deNeuroMetrix, Inc.: NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder ValueFebruary 13, 2024 | markets.businessinsider.comNeuroMetrix Plans Strategic Options To Promote Growth, Maximize Shareholder Value; Stock DropsFebruary 13, 2024 | finance.yahoo.comNeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder ValueSee More Headlines Receive NURO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroMetrix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today6/06/2024Next Earnings (Estimated)7/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NURO CUSIPN/A CIK1289850 Webwww.neurometrix.com Phone(781) 890-9989Fax302-636-5454Employees26Year Founded1996Profitability EPS (Most Recent Fiscal Year)($6.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,530,000.00 Net Margins-151.51% Pretax Margin-151.49% Return on Equity-39.85% Return on Assets-37.08% Debt Debt-to-Equity RatioN/A Current Ratio10.91 Quick Ratio10.11 Sales & Book Value Annual Sales$5.90 million Price / Sales1.28 Cash FlowN/A Price / Cash FlowN/A Book Value$13.18 per share Price / Book0.29Miscellaneous Outstanding Shares2,010,000Free Float1,864,000Market Cap$7.58 million OptionableNot Optionable Beta2.16 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Shai N. Gozani M.D. (Age 59)Ph.D., Founder, Chairman, CEO, President & Secretary Comp: $444.05kMr. Thomas T. Higgins (Age 72)Senior VP, CFO & Treasurer Comp: $347.75kDr. Xuan Kong Ph.D.Chief Data ScientistMs. Susan M. Bell R.N.Senior Vice President of Population Health & Value Based CareKey CompetitorsInspira Technologies Oxy B.H.N.NASDAQ:IINNSpectral AINASDAQ:MDAIT2 BiosystemsNASDAQ:TTOOSeaStar MedicalNASDAQ:ICUFemasysNASDAQ:FEMYView All Competitors NURO Stock Analysis - Frequently Asked Questions How have NURO shares performed in 2024? NeuroMetrix's stock was trading at $3.60 at the beginning of the year. Since then, NURO stock has increased by 4.7% and is now trading at $3.77. View the best growth stocks for 2024 here. When is NeuroMetrix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024. View our NURO earnings forecast. How were NeuroMetrix's earnings last quarter? NeuroMetrix, Inc. (NASDAQ:NURO) released its quarterly earnings data on Thursday, February, 22nd. The medical device company reported ($1.43) earnings per share (EPS) for the quarter. The medical device company had revenue of $1.32 million for the quarter. NeuroMetrix had a negative trailing twelve-month return on equity of 39.85% and a negative net margin of 151.51%. When did NeuroMetrix's stock split? NeuroMetrix shares reverse split on Wednesday, November 22nd 2023. The 1-8 reverse split was announced on Monday, November 20th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. What is Shai N. Gozani's approval rating as NeuroMetrix's CEO? 10 employees have rated NeuroMetrix Chief Executive Officer Shai N. Gozani on Glassdoor.com. Shai N. Gozani has an approval rating of 57% among the company's employees. This puts Shai N. Gozani in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of NeuroMetrix own? Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroMetrix investors own include Merit Medical Systems (MMSI), Palatin Technologies (PTN), Citigroup (C), Salesforce (CRM), Nokia Oyj (NOK), ReWalk Robotics (RWLK), Advanced Micro Devices (AMD) and Vaxart (VXRT). How do I buy shares of NeuroMetrix? Shares of NURO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NURO) was last updated on 6/6/2024 by MarketBeat.com Staff From Our PartnersTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | Sponsored[Webinar] Understanding Covered CallsDiscover the details of this option-selling strategy.OIC | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroMetrix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroMetrix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.